Sialorrhea (drooling, ptyalism) is a common and distressing symptom in corticobasal syndrome (CBS), affecting a significant proportion of patients throughout the disease course. Unlike Parkinson's disease where sialorrhea is primarily due to reduced swallow frequency, in CBS the pathophysiology is more complex, involving both reduced salivary clearance and impaired orofacial motor control. The symptom carries substantial psychosocial burden, impacting quality of life, social interaction, and caregiver well-being.
Sialorrhea occurs in approximately 30-50% of CBS patients[1][2]. The prevalence increases with disease duration and severity, with some studies reporting rates up to 60% in moderate-to-severe stages. Notably:
The mechanisms underlying sialorrhea in CBS are multifactorial, reflecting the distributed neuroanatomical involvement characteristic of corticobasal degeneration:
Impaired orofacial motor control: Degeneration of the premotor cortex, supplementary motor area (SMA), and primary motor cortex disrupts voluntary control of lip closure and oral containment. The dystonia affecting the orofacial region in many CBS patients compounds this by causing involuntary mouth opening.
Reduced spontaneous swallow rate: Basal ganglia involvement leads to decreased automatic/swallowing movements. CBS patients show significantly reduced swallow frequency compared to healthy controls[4].
Hypersecretion: While true hypersecretion is less common, some CBS patients have increased salivary output possibly related to medication effects or autonomic dysfunction.
Cognitive impairment: Executive dysfunction and reduced awareness impair the patient's ability to consciously manage oral secretions.
Sialorrhea in CBS typically presents with:
Assessment of sialorrhea in CBS should include:
History:
Examination:
Sialorrhea in CBS should be differentiated from:
| Condition | Distinguishing Features |
|---|---|
| Parkinson's disease | More prominent during "off" periods; typically later onset |
| PSP | Often earlier and more severe; associated with square wave jerks |
| MSA | Autonomic features prominent; orthostatic hypotension co-occurrence |
| Medication-induced | Temporal relationship to drug initiation |
| Local oral pathology | Dental issues, oral infections |
Behavioral strategies:
Adaptive equipment:
Positioning:
Anticholinergic agents:
| Medication | Dose | Efficacy | Considerations |
|---|---|---|---|
| Glycopyrrolate | 1-2 mg TID | High | Preferred in elderly due to limited CNS penetration |
| Trihexyphenidyl | 1-2 mg TID | High | Risk of cognitive side effects; use with caution in CBS |
| Scopolamine | Transdermal patch | Moderate | Useful for nighttime drooling; anticholinergic burden |
| Atropine drops (sublingual) | 0.5-1 mg BID | High | Off-label; rapid onset |
Side effects of anticholinergics include dry mouth, constipation, urinary retention, and — particularly concerning in CBS — cognitive worsening. Trihexyphenidyl should be used with extreme caution given the existing cognitive impairment in CBS patients.
Botulinum toxin for sialorrhea is the most evidence-supported intervention for moderate-to-severe cases[6][7]:
Target glands:
Technique:
Outcomes:
Safety profile:
For refractory cases:
| Feature | CBS | PSP | MSA |
|---|---|---|---|
| Prevalence of sialorrhea | 30-50% | 20-40% | 25-45% |
| Primary mechanism | Motor, cortical | Autonomic, motor | Autonomic predominant |
| Age of onset | 60-65 years | 60-70 years | 55-65 years |
| Response to botulinum toxin | Good | Good | Good |
Sialorrhea significantly affects multiple domains in CBS:
Comoretto R, et al. Sialorrhea and drooling in Parkinson's disease: prevalence and risk factors. Parkinsonism Relat Disord. 2003. ↩︎
Shahed J, et al. Sialorrhea in Parkinson's disease: a review. Parkinsonism Relat Disord. 2011. ↩︎
Strutt AM, et al. Swallow kinematics and nutritional status in atypical parkinsonism. J Neurol Sci. 2021. ↩︎
Difford J, et al. Swallowing and salivary function in corticobasal syndrome and progressive supranuclear palsy. Dysphagia. 2022. ↩︎
Lahava H, et al. Management of sialorrhea in neurodegenerative diseases: a systematic review. Clin Neurol Neurosurg. 2019. ↩︎
Prashanth LK, et al. Botulinum toxin for sialorrhea in parkinsonian syndromes: a systematic review. J Neural Transm. 2021. ↩︎
Jankovic J, et al. Botulinum toxin for treatment of sialorrhea in atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2018. ↩︎